Filing Flows

Filing Flows › Neurocrine Biosciences (NBIX) › Next earnings date

Neurocrine Biosciences (NBIX) earnings: beat the estimate

Neurocrine Biosciences (NBIX) reported on Nov 2, 2026 and beat the EPS estimate: $3.29 against $2.75 (+19.8%). Revenue was $1.1B for Q3 2026, +41% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+19.8% vs estimate
Beat rate80%

The last report

Neurocrine Biosciences reported revenue of $1.1B for the third quarter 2026 (+41% Y/Y), net earnings $206M. How it makes money → · Every quarter →

Neurocrine Biosciences: EPS against the estimate, last 5 reportsNeurocrine Biosciences: EPS against the estimate, last 5 reportsEstimateReported$2.07$2.17Oct 25$2.30$1.88Feb 26$1.70$1.94May 26$1.96$2.85Jul 26$2.75$3.29Nov 26
Latest (Nov 26): Estimate $2.75, Reported $3.29.
NBIX: the stock's move on each reportNBIX: the stock's move on each reportJul 30, 2026-7.7%May 5, 2026+9.7%Feb 11, 2026-10.6%Oct 28, 2025-7.3%

Neurocrine Biosciences' latest quarter

Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.

Questions

Did Neurocrine Biosciences beat earnings?

Neurocrine Biosciences (NBIX) reported on Nov 2, 2026 and beat the EPS estimate: $3.29 against $2.75 (+19.8%).

When does NBIX report earnings?

The next date is not set yet.

Does Neurocrine Biosciences usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.